SelectQuote, Inc 8-K, filed Aug 25, 2026
SelectQuote, Inc. (SLQT)
8-K
2026-08-25
For: 2026-08-25
View Original
Added on
August 25, 2026
About this 8-K
SelectQuote, Inc filed this 8-K on August 25, 2026.
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________________
FORM 8-K
_______________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 25, 2026
_____________________________________
(Exact name of registrant as specified in its charter)
_____________________________________
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
(Address of principal executive offices) (Zip code) | ||||||||
( | ||||||||
(Registrant’s telephone number, including area code) | ||||||||
No change since last report | ||||||||
(Former Name or Address, If Changed Since Last Report) | ||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 25, 2026, SelectQuote, Inc. reported its financial results for the fourth quarter ended June 30, 2026. Copies of the related press release and investor presentation are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.
These exhibits are being furnished pursuant to Item 2.02, and the information contained therein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall either of them be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description of Exhibit | ||||
| Press Release | |||||
| Investor Presentation | |||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SELECTQUOTE, INC.
Date: August 25, 2026 | By: /s/ Ryan M. Clement | ||||
| Name: Ryan M. Clement | |||||
Title: Chief Financial Officer | |||||
Exhibit 99.1
SelectQuote, Inc. Reports Fourth Quarter of Fiscal Year 2026 Results
Fourth Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights
•Revenue of $321.7 million
•Net loss of $(16.8) million
•Adjusted EBITDA* of $11.9 million
Fiscal Year 2027 Guidance Ranges:
•Revenue expected in a range of $1.35 billion to $1.45 billion
•Adjusted EBITDA* expected in a range of $90 million to $115 million
•Operating Cash Flow expected to be more than $60 million
Fourth Quarter Fiscal Year 2026 – Segment Highlights
Senior
•Revenue of $72.5 million
•Adjusted EBITDA of $8.0 million
•Approved Medicare Advantage policies of 72,180
Healthcare Services
•Revenue of $193.5 million
•Adjusted EBITDA of $12.1 million
•109,039 SelectRx members
Life
•Revenue of $47.9 million
•Adjusted EBITDA of $9.8 million
OVERLAND PARK, Kan., August 25, 2026--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the fourth quarter of fiscal year 2026 of $321.7 million compared to consolidated revenue for the fourth quarter of fiscal year 2025 of $345.1 million. Consolidated net loss for the fourth quarter of fiscal year 2026 was $16.8 million compared to consolidated net income for the fourth quarter of fiscal year 2025 of $12.9 million. Consolidated Adjusted EBITDA* for the fourth quarter of fiscal year 2026 was $11.9 million compared to consolidated Adjusted EBITDA* for the fourth quarter of fiscal year 2025 of $2.7 million. Consolidated cash used in operations during the fourth quarter of fiscal year 2026 was $3.3 million compared to $37.5 million used during the fourth quarter of fiscal year 2025.
SelectQuote reported consolidated revenue for the fiscal year 2026 of $1.6 billion compared to consolidated revenue for fiscal year 2025 of $1.5 billion. Consolidated net income for the fiscal year 2026 was $62.2 million compared to consolidated net income for fiscal year 2025 of $47.6 million. Consolidated Adjusted EBITDA* for the fiscal year 2026 was $109.1 million compared to consolidated Adjusted EBITDA* for the fiscal year 2025 of $126.3 million. Consolidated cash generated from operations was $31.9 million for the fiscal year 2026 compared to consolidated cash used in operations of $11.7 million during the fiscal year 2025. For the fiscal year 2026, SelectQuote improved operating cash flow by $44 million compared to fiscal 2025, driven largely by the scale in Healthcare Services and improved operating efficiency across SelectQuote.
SelectQuote Chief Executive Officer Tim Danker commented, “It was a highly successful 4th quarter and full-year fiscal 2026 for our business. Our Senior Medicare Advantage distribution business excelled through another turbulent year for the industry. Insurance carriers continued to modify policy benefits and optimize volumes but through it all, SelectQuote remained the reliable partner of choice. SelectQuote’s Senior business delivered another strong year with an Adjusted EBITDA margin of 26%, which marks the 4th consecutive year with margins solidly above our long-term 20%+ operating target. We have high confidence in our Senior platform’s ability to generate durable returns across a range of Medicare Advantage environments and view fiscal 2027 as an important year to further compound cash flow while remaining disciplined in our growth investments as carrier profitability improves.”
* See “Non-GAAP Financial Measures” below.
1
“We also increasingly realized our goal to scale Healthcare Services profitability and cash flow through our SelectRx business. We are excited to exit fiscal 2026 with run-rate Adjusted EBITDA of nearly $50 million, which will increasingly drive operating cash flow and ultimately accrue value to our shareholders.”
Mr. Danker continued, “Looking to fiscal 2027, we have conviction that the $44 million improvement in operating cash flow in fiscal 2026 will continue. As we have emphasized, our highest strategic priority is to deliver shareholder value through growth in profitability and scaled cash flow. In the year ahead, we plan to accelerate equity value accretion in multiple ways. Exiting 2026, we have successfully implemented technology-enabled workstream efficiencies that we expect will drive annual expense savings of over $30 million. Paired with the demonstrated durability of our Senior profitability and continued scale of Healthcare Services, we expect full-year 2027 operating cash flow to approximately double to over $60 million, with free cash flow generation of around $50 million. Best of all, we see opportunity to compound cash flow growth in the future through continued optimization of our leverage and funding costs, and we are excited to deliver this value to our shareholders in the years ahead.”
Segment Results
We currently have three reportable segments: 1) Senior, 2) Healthcare Services and 3) Life. The performance measures of the segments include total revenue and adjusted EBITDA. Costs of commissions and other services revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount.
Senior
Financial Results
The following table provides the financial results for the Senior segment for the periods presented:
| Three Months Ended June 30, | Year Ended June 30, | |||||||||||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | % Change | 2026 | 2025 | % Change | ||||||||||||||||||||||||||
| Revenue | $ | 72,522 | $ | 82,464 | (12) | % | $ | 575,947 | $ | 600,393 | (4) | % | ||||||||||||||||||||
| Adjusted EBITDA | 7,969 | 7,722 | 3 | % | 148,026 | 161,671 | (8) | % | ||||||||||||||||||||||||
| Adjusted EBITDA Margin | 11 | % | 9 | % | 26 | % | 27 | % | ||||||||||||||||||||||||
Operating Metrics
Submitted Policies
Submitted policies are counted when an individual completes an application with our licensed agent and provides authorization to the agent to submit the application to the insurance carrier partner. The applicant may have additional actions to take before the application will be reviewed by the insurance carrier.
The following table shows the number of submitted policies for the periods presented:
| Three Months Ended June 30, | Year Ended June 30, | |||||||||||||||||||||||||||||||
| 2026 | 2025 | % Change | 2026 | 2025 | % Change | |||||||||||||||||||||||||||
| Medicare Advantage | 69,653 | 85,979 | (19) | % | 622,939 | 674,851 | (8) | % | ||||||||||||||||||||||||
All other (1) | 18,621 | 21,438 | (13) | % | 90,253 | 87,413 | 3 | % | ||||||||||||||||||||||||
| Total | 88,274 | 107,417 | (18) | % | 713,192 | 762,264 | (6) | % | ||||||||||||||||||||||||
(1) Represents the submitted policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.
2
Approved Policies
Approved policies represents the number of submitted policies that were approved by our insurance carrier partners for the identified product during the indicated period. Not all approved policies will go in force.
The following table shows the number of approved policies for the periods presented:
| Three Months Ended June 30, | Year Ended June 30, | |||||||||||||||||||||||||||||||
| 2026 | 2025 | % Change | 2026 | 2025 | % Change | |||||||||||||||||||||||||||
| Medicare Advantage | 72,180 | 85,344 | (15) | % | 567,526 | 592,874 | (4) | % | ||||||||||||||||||||||||
All other (1) | 15,968 | 19,979 | (20) | % | 71,298 | 70,295 | 1 | % | ||||||||||||||||||||||||
| Total | 88,148 | 105,323 | (16) | % | 638,824 | 663,169 | (4) | % | ||||||||||||||||||||||||
(1) Represents the approved policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.
Lifetime Value of Commissions per Approved Policy
Lifetime value of commissions per approved policy represents commissions estimated to be collected over the estimated life of an approved policy based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints. The lifetime value of commissions per approved policy is equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions.
The following table shows the lifetime value of commissions per approved policy for the periods presented:
| Three Months Ended June 30, | Year Ended June 30, | |||||||||||||||||||||||||||||||
| (dollars per policy): | 2026 | 2025 | % Change | 2026 | 2025 | % Change | ||||||||||||||||||||||||||
| Medicare Advantage | $ | 883 | $ | 837 | 5 | % | $ | 873 | $ | 884 | (1) | % | ||||||||||||||||||||
All other(1) | 130 | 125 | 4 | % | 122 | 134 | (9) | % | ||||||||||||||||||||||||
(1) Represents the weighted average LTV per approved policy.
Healthcare Services
Financial Results
The following table provides the financial results for the Healthcare Services segment for the periods presented:
| Three Months Ended June 30, | Year Ended June 30, | |||||||||||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | % Change | 2026 | 2025 | % Change | ||||||||||||||||||||||||||
| Revenue | $ | 193,544 | $ | 214,028 | (10) | % | $ | 844,935 | $ | 742,705 | 14 | % | ||||||||||||||||||||
| Adjusted EBITDA | 12,146 | 11,853 | 2 | % | 25,483 | 25,387 | — | % | ||||||||||||||||||||||||
| Adjusted EBITDA Margin | 6 | % | 6 | % | 3 | % | 3 | % | ||||||||||||||||||||||||
Operating Metrics
Members
The total number of SelectRx members represents the amount of active customers to which an order has been shipped and the prescriptions per day represents the total average prescriptions shipped per business day. These two metrics are the primary drivers of revenue for Healthcare Services.
The following table shows the total number of SelectRx members as of the periods presented:
3
| June 30, 2026 | June 30, 2025 | |||||||||||||||||||||||||
| Total SelectRx Members | 109,039 | 108,018 | ||||||||||||||||||||||||
The total number of SelectRx members increased by 1% as of June 30, 2026, compared to June 30, 2025, due to a growth in membership during the AEP season.
The following table shows the average prescriptions shipped per day for the periods presented:
| Three Months Ended June 30, | Year Ended June 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
Prescriptions Per Day | 31,711 | 30,630 | 32,215 | 27,867 | ||||||||||||||||||||||
Combined Senior and Healthcare Services - Consumer Per Unit Economics
Combined Senior and Healthcare Services consumer per unit economics represents total MA and MS commissions; other product commissions; other revenues, including revenues from Healthcare Services; and operating expenses associated with Senior and Healthcare Services, each shown per number of approved MA and MS policies over a given time period. Management assesses the business on a per-unit basis to help ensure that the revenue opportunity associated with a successful policy sale is attractive relative to the marketing acquisition cost. Because not all acquired leads result in a successful policy sale, all per-policy metrics are based on approved policies, which is the measure that triggers revenue recognition.
The MA and MS commission per MA/MS policy represents the LTV for policies sold in the period. Other commission per MA/MS policy represents the LTV for other products sold in the period, including DVH prescription drug plan, and other products, which management views as additional commission revenue on our agents’ core function of MA/MS policy sales. Pharmacy revenue per MA/MS policy represents revenue from SelectRx, and other revenue per MA/MS policy represents revenue from Healthcare Select, production bonuses, marketing development funds, lead generation revenue, and adjustments from the Company’s reassessment of its cohorts’ transaction prices. Total operating expenses per MA/MS policy represents all of the operating expenses within Senior and Healthcare Services. The revenue to customer acquisition cost (“CAC”) multiple represents total revenue as a multiple of total marketing acquisition cost, which represents the direct costs of acquiring leads. These costs are included in marketing and advertising expense within the total operating expenses per MA/MS policy.
The following table shows combined Senior and Healthcare Services consumer per unit economics for the periods presented. Based on the seasonality of Senior and the fluctuations between quarters, we believe that the most relevant view of per unit economics is on a rolling 12-month basis. All per MA/MS policy metrics below are based on the sum of approved MA/MS policies, as both products have similar commission profiles.
4
| Twelve Months Ended June 30, | |||||||||||||||||
| (dollars per approved policy): | 2026 | 2025 | |||||||||||||||
| MA and MS approved policies | 569,698 | 594,572 | |||||||||||||||
| MA and MS commission per MA / MS policy | $ | 875 | $ | 885 | |||||||||||||
| Other commission per MA/MS policy | 10 | 12 | |||||||||||||||
| Pharmacy revenue per MA/MS policy | 1,458 | 1,219 | |||||||||||||||
| Other revenue per MA/MS policy | 151 | 86 | |||||||||||||||
| Total revenue per MA / MS policy | 2,494 | 2,202 | |||||||||||||||
| Total operating expenses per MA / MS policy | (2,189) | (1,937) | |||||||||||||||
| Adjusted EBITDA per MA/MS policy | $ | 305 | $ | 265 | |||||||||||||
| Adjusted EBITDA Margin per MA/MS policy | 12 | % | 12 | % | |||||||||||||
| Revenue / CAC multiple | 6.8X | 6.1X | |||||||||||||||
Total revenue per MA/MS policy increased 13% for the twelve months ended June 30, 2026, compared to the twelve months ended June 30, 2025, primarily due to the increase in pharmacy revenue. Total operating expenses per MA/MS policy increased 13% for the twelve months ended June 30, 2026, compared to the twelve months ended June 30, 2025, driven by an increase in cost of goods sold-pharmacy revenue for Healthcare Services due to the growth of the business.
Life
Financial Results
The following table provides the financial results for the Life segment for the periods presented:
| Three Months Ended June 30, | Year Ended June 30, | |||||||||||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | % Change | 2026 | 2025 | % Change | ||||||||||||||||||||||||||
| Revenue | $ | 47,873 | $ | 47,984 | — | % | $ | 186,039 | $ | 172,978 | 8 | % | ||||||||||||||||||||
| Adjusted EBITDA | 9,776 | 6,922 | 41 | % | 27,012 | 26,669 | 1 | % | ||||||||||||||||||||||||
| Adjusted EBITDA Margin | 20 | % | 14 | % | 15 | % | 15 | % | ||||||||||||||||||||||||
Operating Metrics
Life premium represents the total premium value for all policies that were approved by the relevant insurance carrier partner and for which the policy document was sent to the policyholder and payment information was received by the relevant insurance carrier partner during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Life segment.
The following table shows term and final expense premiums for the periods presented:
| Three Months Ended June 30, | Year Ended June 30, | ||||||||||||||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | % Change | 2026 | 2025 | % Change | |||||||||||||||||||||||||||||
| Term Premiums | $ | 19,151 | $ | 19,989 | (4) | % | $ | 75,230 | $ | 71,448 | 5 | % | |||||||||||||||||||||||
| Final Expense Premiums | 25,855 | 30,807 | (16) | % | 109,927 | 105,099 | 5 | % | |||||||||||||||||||||||||||
| Total | $ | 45,006 | $ | 50,796 | (11) | % | $ | 185,157 | $ | 176,547 | 5 | % | |||||||||||||||||||||||
Earnings Conference Call
5
SelectQuote, Inc. will host a conference call with the investment community on August 25, 2026, beginning at 8:30 a.m. ET. We encourage interested parties to access the live webcast of the event via our investor relations website https://ir.selectquote.com/investor-home/default.aspx or via this link: https://events.q4inc.com/attendee/890240794.
For those interested in dialing into the conference call, please register using this link: https://events.q4inc.com/analyst/890240794?pwd=z46TrijY. After registering, a confirmation will be sent via email, including dial-in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call we suggest registering at least 10 minutes before the start of the call.
Non-GAAP Financial Measures
This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA, which, when presented on a consolidated basis, is a non-GAAP financial measure. This non-GAAP financial measure is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to any similarly titled measure presented by other companies. We define Adjusted EBITDA as net income plus interest expense, income taxes, depreciation and amortization, changes in fair value of warrant liabilities, loss on extinguishment of debt, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure is net income. We monitor and have presented in this release Adjusted EBITDA because it is a key measure used by our management and Board of Directors to understand and evaluate our operating performance, establish budgets, and develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance.
A reconciliation of the differences between Adjusted EBITDA and its most directly comparable GAAP measure, net income, is presented below on page 13. The Company is unable to provide a quantitative reconciliation of forward-looking Adjusted EBITDA to its most directly comparable GAAP measure without unreasonable effort because it is not possible to predict certain information included in the calculation of such GAAP measure, including the fair value of outstanding warrants to purchase shares of the Company's common stock. The unavailable information could have a significant impact on the Company’s GAAP financial results.
Forward Looking Statements
This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as “may,” “should,” “could,” “predict,” “potential,” “believe,” “will likely result,” “expect,” “continue,” “will,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “projection,” “would” and “outlook,” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead
6
providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost-effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; potential litigation and other legal proceedings or inquiries; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; our ability to regain and maintain compliance with NYSE listing standards; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers’ approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, changes in reimbursement rates under our contracts with pharmacy benefit managers, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled “Risk Factors” in the most recent Annual Report on Form 10-K (the “Annual Report”) and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.
About SelectQuote:
Founded in 1985, SelectQuote (NYSE: SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote’s success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care.
With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select which proactively connects consumers with a wide breadth of healthcare services supporting their needs.
Investor Relations:
Sloan Bohlen
877-678-4083
investorrelations@selectquote.com
Media:
Matt Gunter
913-286-4931
matt.gunter@selectquote.com
Source: SelectQuote, Inc.
7
SELECTQUOTE, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands)
| June 30, 2026 | June 30, 2025 | |||||||||||||
| ASSETS | ||||||||||||||
| CURRENT ASSETS: | ||||||||||||||
| Cash, cash equivalents, and restricted cash | $ | 20,718 | $ | 35,733 | ||||||||||
| Accounts receivable, net of allowances of $7.1 million and $11.8 million, respectively | 166,825 | 151,388 | ||||||||||||
| Commissions receivable-current | 138,728 | 132,077 | ||||||||||||
| Other current assets | 24,676 | 21,844 | ||||||||||||
| Total current assets | 350,947 | 341,042 | ||||||||||||
| COMMISSIONS RECEIVABLE—Net | 852,675 | 818,751 | ||||||||||||
| PROPERTY AND EQUIPMENT—Net | 12,050 | 14,577 | ||||||||||||
| SOFTWARE—Net | 18,072 | 15,060 | ||||||||||||
| OPERATING LEASE RIGHT-OF-USE ASSETS | 20,511 | 24,635 | ||||||||||||
| INTANGIBLE ASSETS—Net | 839 | 1,973 | ||||||||||||
| GOODWILL | 29,438 | 29,438 | ||||||||||||
| OTHER ASSETS | 2,296 | 3,880 | ||||||||||||
| TOTAL ASSETS | $ | 1,286,828 | $ | 1,249,356 | ||||||||||
| LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS’ EQUITY | ||||||||||||||
| CURRENT LIABILITIES: | ||||||||||||||
| Accounts payable | $ | 74,033 | $ | 59,205 | ||||||||||
| Accrued expenses | 21,049 | 13,856 | ||||||||||||
| Accrued compensation and benefits | 62,265 | 58,788 | ||||||||||||
| Operating lease liabilities—current | 4,448 | 4,820 | ||||||||||||
| Current portion of long-term debt | 22,014 | 68,523 | ||||||||||||
| Other current liabilities | 8,814 | 7,718 | ||||||||||||
| Total current liabilities | 192,623 | 212,910 | ||||||||||||
| LONG-TERM DEBT, NET—less current portion | 348,154 | 316,589 | ||||||||||||
| DEFERRED INCOME TAXES | 49,453 | 37,872 | ||||||||||||
| OPERATING LEASE LIABILITIES | 21,753 | 25,982 | ||||||||||||
| OTHER LIABILITIES | 24,820 | 80,485 | ||||||||||||
| Total liabilities | 636,803 | 673,838 | ||||||||||||
8
| June 30, 2026 | June 30, 2025 | |||||||||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||||||||
| PREFERRED STOCK: | ||||||||||||||
| Senior Non-Convertible Preferred Stock, $0.01 par value, 350,000 shares issued and outstanding as of June 30, 2026 and 2025, respectively, current liquidation preference of $423.2 million and $367.1 million as of June 30, 2026 and 2025, respectively. | 298,213 | 224,374 | ||||||||||||
| SHAREHOLDERS’ EQUITY: | ||||||||||||||
| Common stock, $0.01 par value | 1,765 | 1,728 | ||||||||||||
| Additional paid-in capital | 510,047 | 571,605 | ||||||||||||
| Accumulated deficit | (160,000) | (222,189) | ||||||||||||
| Total shareholders’ equity | 351,812 | 351,144 | ||||||||||||
| TOTAL LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS’ EQUITY | $ | 1,286,828 | $ | 1,249,356 | ||||||||||
9
SELECTQUOTE, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Unaudited)
(In thousands)
| Three Months Ended June 30, | Year Ended June 30, | ||||||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||||||
| REVENUE: | |||||||||||||||||||||||||||||
Commissions and other services | $ | 131,822 | $ | 134,503 | $ | 787,645 | $ | 797,841 | |||||||||||||||||||||
| Pharmacy | 189,831 | 210,599 | 830,854 | 728,753 | |||||||||||||||||||||||||
| Total revenue | 321,653 | 345,102 | 1,618,499 | 1,526,594 | |||||||||||||||||||||||||
| OPERATING COSTS AND EXPENSES: | |||||||||||||||||||||||||||||
Cost of commissions and other services revenue | 56,750 | 58,844 | 312,153 | 305,127 | |||||||||||||||||||||||||
| Cost of goods sold—pharmacy revenue | 161,486 | 182,312 | 730,748 | 630,340 | |||||||||||||||||||||||||
| Marketing and advertising | 54,231 | 65,283 | 313,687 | 319,505 | |||||||||||||||||||||||||
| Selling, general, and administrative | 36,075 | 41,591 | 149,022 | 164,442 | |||||||||||||||||||||||||
| Technical development | 9,682 | 9,594 | 38,965 | 38,681 | |||||||||||||||||||||||||
| Total operating costs and expenses | 318,224 | 357,624 | 1,544,575 | 1,458,095 | |||||||||||||||||||||||||
| INCOME (LOSS) FROM OPERATIONS | 3,429 | (12,522) | 73,924 | 68,499 | |||||||||||||||||||||||||
| INTEREST EXPENSE, NET | (10,504) | (12,226) | (44,527) | (79,385) | |||||||||||||||||||||||||
CHANGE IN FAIR VALUE OF WARRANTS | (6,017) | 34,181 | 55,804 | 59,525 | |||||||||||||||||||||||||
LOSS ON EXTINGUISHMENT OF DEBT | — | — | (8,659) | — | |||||||||||||||||||||||||
| OTHER EXPENSE, NET | (38) | (58) | (255) | (128) | |||||||||||||||||||||||||
| INCOME (LOSS) BEFORE INCOME TAX EXPENSE (BENEFIT) | (13,130) | 9,375 | 76,287 | 48,511 | |||||||||||||||||||||||||
| INCOME TAX EXPENSE (BENEFIT) | 3,712 | (3,493) | 14,098 | 931 | |||||||||||||||||||||||||
| NET INCOME (LOSS) | $ | (16,842) | $ | 12,868 | $ | 62,189 | $ | 47,580 | |||||||||||||||||||||
Senior Non-Convertible Preferred Stock accumulated dividends and accretion | (19,456) | (16,762) | (73,838) | (22,548) | |||||||||||||||||||||||||
| NET INCOME (LOSS) ATTRIBUTABLE TO COMMON SHAREHOLDERS | $ | (36,298) | $ | (3,894) | $ | (11,649) | $ | 25,032 | |||||||||||||||||||||
| NET INCOME (LOSS) ATTRIBUTABLE TO COMMON SHAREHOLDERS PER SHARE: | |||||||||||||||||||||||||||||
| Basic | $ | (0.19) | $ | (0.02) | $ | (0.06) | $ | 0.14 | |||||||||||||||||||||
| Diluted | $ | (0.19) | $ | (0.02) | $ | (0.06) | $ | 0.01 | |||||||||||||||||||||
| WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS: | |||||||||||||||||||||||||||||
| Basic | 189,854 | 184,201 | 188,174 | 176,148 | |||||||||||||||||||||||||
| Diluted | 189,854 | 184,201 | 188,174 | 181,895 | |||||||||||||||||||||||||
10
| Three Months Ended June 30, | Year Ended June 30, | ||||||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||||||
| OTHER COMPREHENSIVE LOSS, NET OF TAX: | |||||||||||||||||||||||||||||
| Unrealized loss, net of related tax benefit for the three months ended June 30, 2026, and 2025 of $0.0 million and $0.0 million, and for the year ended June 30, 2026, and 2025, of $0.0 million,and $0.1 million. | — | — | — | (432) | |||||||||||||||||||||||||
| Amount reclassified into earnings, net of related tax benefit for the three months ended June 30, 2026 and 2025 of $0.0 million and $0.0 million, and for the year ended June 30, 2026, and 2025, of $0.0 million, and $1.3 million. | — | — | — | (3,680) | |||||||||||||||||||||||||
OTHER COMPREHENSIVE LOSS | — | — | — | (4,112) | |||||||||||||||||||||||||
| COMPREHENSIVE INCOME (LOSS) | $ | (16,842) | $ | 12,868 | $ | 62,189 | $ | 43,468 | |||||||||||||||||||||
11
SELECTQUOTE, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
| Three Months Ended June 30, | Year Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||||||||||||||||||
| Net income (loss) | $ | (16,842) | $ | 12,868 | $ | 62,189 | $ | 47,580 | |||||||||||||||
| Adjustments to reconcile net income (loss) to net cash, cash equivalents, and restricted cash provided by (used in) operating activities: | |||||||||||||||||||||||
| Depreciation and amortization | 4,482 | 4,876 | 17,489 | 20,460 | |||||||||||||||||||
| Loss on disposal of property, equipment, and software | — | 80 | — | 240 | |||||||||||||||||||
| Impairment of long-lived assets | — | 4,209 | — | 4,209 | |||||||||||||||||||
| Impairment of equity-method investment | — | — | 1,000 | — | |||||||||||||||||||
| Loss on extinguishment of debt | — | — | 8,659 | — | |||||||||||||||||||
| Share-based compensation expense | 3,382 | 4,852 | 14,862 | 18,357 | |||||||||||||||||||
| Deferred income taxes | 4,242 | (2,576) | 11,581 | 1,849 | |||||||||||||||||||
| Amortization of debt issuance costs and debt discount | 950 | 1,367 | 4,293 | 5,247 | |||||||||||||||||||
| Write-off of debt issuance costs | — | — | — | 93 | |||||||||||||||||||
| Accrued interest payable in kind | — | 713 | — | 14,013 | |||||||||||||||||||
| Change in fair value of warrants | 6,017 | (34,181) | (55,804) | (59,525) | |||||||||||||||||||
| Non-cash lease expense | 1,054 | 1,072 | 4,124 | 3,922 | |||||||||||||||||||
| Bad debt expense | — | — | — | 4,203 | |||||||||||||||||||
| Changes in operating assets and liabilities: | |||||||||||||||||||||||
| Accounts receivable, net | 67,466 | 33,491 | (15,437) | (5,555) | |||||||||||||||||||
| Commissions receivable | (31,874) | (35,745) | (40,576) | (69,510) | |||||||||||||||||||
| Other assets | (3,723) | (5,938) | (2,460) | (6,282) | |||||||||||||||||||
| Accounts payable and accrued expenses | (31,689) | (21,936) | 21,894 | 19,226 | |||||||||||||||||||
| Operating lease liabilities | (1,143) | (1,137) | (4,602) | (4,711) | |||||||||||||||||||
| Other liabilities | (5,642) | 503 | 4,673 | (5,482) | |||||||||||||||||||
| Net cash provided by (used in) operating activities | (3,320) | (37,482) | 31,885 | (11,666) | |||||||||||||||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||||||||||||||||||
| Purchases of property and equipment | (1,183) | (501) | (4,276) | (2,191) | |||||||||||||||||||
| Purchases of software and capitalized software development costs | (3,379) | (2,610) | (11,870) | (9,123) | |||||||||||||||||||
| Net cash used in investing activities | (4,562) | (3,111) | (16,146) | (11,314) | |||||||||||||||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||||||||||||||||||
| Proceeds from revolving credit facility | 88,000 | — | 358,000 | 166,900 | |||||||||||||||||||
| Payments on revolving credit facility | (88,000) | — | (358,000) | (166,900) | |||||||||||||||||||
| Net proceeds from Term Loan | — | — | 315,234 | — | |||||||||||||||||||
| Payments on Term Loans | (2,031) | (3,573) | (316,031) | (388,216) | |||||||||||||||||||
| Proceeds from ABS Notes | — | — | — | 99,095 | |||||||||||||||||||
| Payments on ABS Notes | (4,513) | (4,855) | (19,529) | (16,577) | |||||||||||||||||||
| Payments on other debt | (146) | (108) | (527) | (312) | |||||||||||||||||||
| Proceeds from common stock options exercised and employee stock purchase plan | — | (14) | — | 98 | |||||||||||||||||||
| Proceeds from issuance of Senior Non-Convertible Preferred Stock | — | — | — | 337,855 | |||||||||||||||||||
| Senior Non-Convertible Preferred Stock issuance costs | — | — | — | (7,076) | |||||||||||||||||||
| Payments of tax withholdings related to net share settlement of equity awards | (7) | (13) | (2,545) | (5,032) | |||||||||||||||||||
| Payments of debt issuance costs | — | — | (7,730) | (2,479) | |||||||||||||||||||
| Net cash (used in) provided by financing activities | (6,697) | (8,563) | (31,128) | 17,356 | |||||||||||||||||||
| NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | (14,579) | (49,156) | (15,389) | (5,624) | |||||||||||||||||||
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH —Beginning of period | 36,256 | 86,222 | 37,066 | 42,690 | |||||||||||||||||||
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH —End of period | $ | 21,677 | $ | 37,066 | $ | 21,677 | $ | 37,066 | |||||||||||||||
12
RECONCILIATION OF NON-GAAP MEASURE
SELECTQUOTE, INC. AND SUBSIDIARIES
Reconciliation of Net income (loss) to Adjusted EBITDA
(Unaudited)
| Three Months Ended June 30, | Year Ended June 30, | ||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Net income (loss) | $ | (16,842) | $ | 12,868 | $ | 62,189 | $ | 47,580 | |||||||||||||||
| Share-based compensation expense | 3,382 | 4,852 | 14,862 | 18,357 | |||||||||||||||||||
| Transaction costs | 634 | 1,257 | 2,112 | 14,617 | |||||||||||||||||||
| Depreciation and amortization | 4,482 | 4,876 | 17,489 | 20,460 | |||||||||||||||||||
| Loss on disposal of property, equipment, and software, net | — | 80 | — | 240 | |||||||||||||||||||
Impairment of equity-method investment | — | — | 1,000 | — | |||||||||||||||||||
| Impairment of long-lived asset | — | 4,209 | — | 4,209 | |||||||||||||||||||
Loss on extinguishment of debt | — | — | 8,659 | — | |||||||||||||||||||
| Change in fair value of warrants | 6,017 | (34,181) | (55,804) | (59,525) | |||||||||||||||||||
| Interest expense, net | 10,504 | 12,226 | 44,527 | 79,385 | |||||||||||||||||||
| Income tax expense | 3,712 | (3,493) | 14,098 | 931 | |||||||||||||||||||
| Adjusted EBITDA | $ | 11,889 | $ | 2,694 | $ | 109,132 | $ | 126,254 | |||||||||||||||
13
4th Quarter Fiscal 2026 Earnings Presentation August 25, 2026 Exhibit 99.2
Forward-Looking Statements This presentation contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as “may,” “should,” “could,” “predict,” “potential,” “believe,” “will likely result,” “expect,” “continue,” “will,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “projection,” “would” and “outlook,” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost- effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; potential litigation and other legal proceedings or inquiries; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; our ability to regain and maintain compliance with NYSE listing standards; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers’ approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, changes in reimbursement rates under our contracts with pharmacy benefit managers, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled “Risk Factors” in the most recent Annual Report on Form 10-K (the “Annual Report”) and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. No Offer or Solicitation; Further Information This presentation is for informational purposes only and is not an offer to sell with respect to any securities. This presentation should be read together with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements and the related notes thereto included in the Annual Report and subsequent quarterly reports. Non-GAAP Financial Measures This presentation includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this presentation Adjusted EBITDA, which, when presented on a consolidated basis, is a non-GAAP financial measure. This non-GAAP financial measure is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to any similarly titled measure presented by other companies. We define Adjusted EBITDA as net income (loss) plus interest expense, income taxes, depreciation and amortization, changes in fair value of warrant liabilities, loss on extinguishment of debt, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure for Adjusted EBITDA is net income (loss). We monitor and have presented in this presentation Adjusted EBITDA because it is a key measure used by our management and Board of Directors in understanding and evaluating our operating performance, establishing budgets, and developing operational goals for managing our business. In particular, we believe that excluding the impact of certain expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance. For further discussion regarding this non-GAAP measure, please see today’s press release. A reconciliation of the differences between Adjusted EBITDA and its most directly comparable GAAP financial measure, net income (loss), is set forth below on slide 13. The Company is unable to provide a quantitative reconciliation of forward-looking Adjusted EBITDA to its most directly comparable GAAP measure without unreasonable effort because it is not possible to predict certain items included in the calculation of such GAAP measure, including the fair value of outstanding warrants to purchase shares of the Company's common stock. The unavailable information could have a significant impact on the Company's GAAP financial results. Disclaimer 2
26% Adj. EBITDA Margin Healthcare Services Senior Cash Flow 3 SelectQuote Year-in-Review $40M+ Year-over-Year improvement in Operating Cash Flow ~$50M Annualized Adj. EBITDA Exit Run-Rate
Technology Advantage Leads to Operating Efficiencies • Optimized end-to-end sales funnel maximizing agent efficiency • Streamlined corporate functions with focus on enhancing associate and agent toolkit • AI and technology efficiencies lead directly to cash savings without sacrificing productivity $30M+ in annual cost savings for FY 2027 Revenue Operations AI-assisted engine to complement carrier commission data entry and research Modernized business model 4 Agent Sales Assist Streamlined agent workflow with scalable AI intelligence platform Quality Assurance Ability to listen to entirety of every call enabled by AI with real- time coaching and call monitoring Enrollment Support Voice AI allows us to instantly scale up or down based on demand while preserving agent talk time Pharmacy Management System (PMS) Custom-built system that unlocks continued operational efficiency gains
Revenue $MM Adjusted EBITDA* $MM $1,527 $1,618 FY25 FY26 $126 $109 FY25 FY26 2026 Consolidated Financial Summary $345 $322 4Q25 4Q26 $3 $12 4Q25 4Q26 *See "Non-GAAP Financial Measures" section on slide 2 5
$(12) $32 FY25 FY26 Operating Cash Flow $MM Commentary 6 Growing Operating Cash Flow • $44 million year-over-year improvement in operating cash driven by disciplined execution across every division • Strong Senior operating results despite a dynamic market backdrop • Healthcare Services driving more operating cash per member • Strong cash contribution in the Life segment
Revenue $MM Adjusted EBITDA $MM $600 $576 FY25 FY26 $162 $148 FY25 FY26 Senior Financial Summary $82 $73 4Q25 4Q26 $8 $8 4Q25 4Q26 7
$214 $221 $231 $199 $194 SELECTRX Members 108 107 113 117 109 4Q25 1Q26 2Q26 3Q26 4Q26 Revenue & Adjusted EBITDA $MM $12 $7 $1 $5 $12 4Q25 1Q26 2Q26 3Q26 4Q26 Healthcare Services KPIs REVENUE ADJUSTED EBITDA 8 PBM partner reimbursement negotiation impact
Revenue $MM Adjusted EBITDA $MM $173 $186 FY25 FY26 $27 $27 FY25 FY26 Life Financial Summary $48 $48 4Q25 4Q26 $7 $10 4Q25 4Q26 9
FY27 Guidance - Driving Significant Cash Flow Improvement 10 Revenue -14% YoY At the Midpoint$1.35B to $1.45B Operating Cash Flow +88% YoY$60M+ Adjusted EBITDA* -6% YoY At the Midpoint$90M to $115M *See "Non-GAAP Financial Measures" section on slide 2
$(12) $32 FY25A FY26A FY27E Operating Cash Flow $MM Commentary 11 $60+ Cash Flow Growth in FY27 • Increasing operational and cost efficiency through technology leverage • PBM stability maintained through multi-year contract • Ramping SelectRx profitability ◦ Driven by the Kansas SelectRx facility
Supplemental Information 12
Reconciliation of Non-GAAP Measure Reconciliation of Net Income to Adjusted EBITDA 13 4Q FY FY YTD (in thousands) 2026 2025 2026 2025 Net income (loss) $ (16,842) $ 12,868 $ 62,189 $ 47,580 Share-based compensation expense 3,382 4,852 14,862 18,357 Transaction costs 634 1,257 2,112 14,617 Depreciation and amortization 4,482 4,876 17,489 20,460 Loss on disposal of property, equipment, and software, net — 80 — 240 Impairment of equity-method investment — — 1,000 — Impairment of long-lived asset — 4,209 — 4,209 Loss on extinguishment of debt — — 8,659 — Change in fair value of warrants 6,017 (34,181) (55,804) (59,525) Interest expense, net 10,504 12,226 44,527 79,385 Income tax expense 3,712 (3,493) 14,098 931 Adjusted EBITDA $ 11,889 $ 2,694 $ 109,132 $ 126,254
SelectQuote Inc. 6800 West 115th Street Suite 2511 Overland Park, Kansas 66211 Phone: (877) 678-4086 Investor Relations investorrelations@selectquote.com 14